A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety
profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or
recurrent non-Hodgkin B-cell lymphomas.